Literature DB >> 2863504

Combined treatment with buserelin and cyproterone acetate in metastatic prostatic carcinoma.

J G Klign, H J de Voogt, F H Schröder, F H de Jong.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2863504     DOI: 10.1016/s0140-6736(85)90415-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 3.  Luteinizing hormone-releasing hormone and its analogues: a review of biological properties and clinical uses.

Authors:  B J Furr; J R Woodburn
Journal:  J Endocrinol Invest       Date:  1988 Jul-Aug       Impact factor: 4.256

Review 4.  Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?

Authors:  R Scaletscky; J A Smith
Journal:  Drug Saf       Date:  1993-04       Impact factor: 5.606

5.  Flare Associated with LHRH-Agonist Therapy.

Authors:  I M Thompson
Journal:  Rev Urol       Date:  2001

6.  Challenges with luteinizing hormone-releasing hormone agonists: flare and surge.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

7.  Androgen deprivation therapy: a cornerstone in the treatment of advanced prostate cancer.

Authors:  Michael K Brawer
Journal:  Rev Urol       Date:  2004

Review 8.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

Review 9.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

Review 10.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.